
Bioorganic and Medicinal Chemistry Letters p. 1090 - 1093 (2019)
Update date:2022-08-29
Topics:
Li, Shiyu
Lv, Xiao
Cheng, Kai
Tian, Yongbing
Huang, Xufeng
Kong, Haiyan
Duan, Yajun
Han, Jihong
Liao, Chenzhong
Xie, Zhouling
Inhibition of MAO-B has been an effective strategy for the treatment of Parkinson's disease. To find more potent and selective MAO-B inhibitors with novel chemical scaffold, we designed and synthesized a series of new 2,3-dihydro-1H-inden-1-amine derivatives on basis of our previous study. Furthermore, the corresponding structure-activity relationship (SAR) of these compounds is detailedly discussed. Compounds L4 (IC50 = 0.11 μM), L8 (IC50 = 0.18 μM), L16 (IC50 = 0.27 μM) and L17 (IC50 = 0.48 μM) showed similar MAO-B inhibitory activity as Selegiline. Moreover, L4, L16 and L17 also exhibited comparable selectivity with Selegiline, indicating that L4, L16 and L17 could be promising selective MAO-B inhibitors for further study.
View MoreContact:13357117572
Address:No.149 Shiji dadao Road.
website:http://www.eastarchem.com/
Contact:1-800-898-2436
Address:1215 K Street, STE 1700
SuZhou Ascepion Pharmaceuticals, Inc.(expird)
Contact:0512-86881668
Address:Building C,68Xingqing Road,Suzhou,China.
jiangsu senxuan pharmaceutical and chemical co.,ltd
Contact:86-523-87982810
Address:hongqiao industrial zone,taixing,jiangsu china
Zhejiang Golden-Shell Pharmaceutical Co.,Ltd.
Contact:+86-576-87501888 / 87501988
Address:No.89 Zhongxing Road. Li'ao, Yuhuan, Zhejiang, China
Doi:10.1016/S0040-4020(01)90441-7
(1994)Doi:10.1002/ejic.201900164
(2019)Doi:10.1021/op034120d
(2003)Doi:10.1134/S1070427208040332
(2008)Doi:10.1139/v01-032
(2001)Doi:10.1139/v73-139
(1973)